This biotechnology is about ex vivo transfection of messenger RNA to stem cells.

A solution of messenger RNA is mixed to a solution of our peptide, pepMB1, to form peptiplexes. These latter have been shown to deliver a large amount of mRNA to stem cells.

Peptides are biodegradables. Therefore, peptide, mRNA and mRNA-coded protein will all be broken down to aminoacids and nucleotides by intracellular proteases and RNases. Moreover, our second-generation mRNA (Aegis™) and pepMB1 do not possess any chemical modification that might be toxic to stem cells.

Asclepios gives rise to a very high level of mRNA-coded protein expression (luciferase activity over 109 RLU / mg of proteins, 16h post-transfection). Furthermore, in vitro transfected stem cells transiently express any protein of interest for several weeks (over 105 RLU / mg of proteins for three weeks).

One may choose the level of protein expression, 24 hours post-transfection, and the duration of protein expression by selecting the right mRNA 5’UTR, mRNA amount, transfection duration and amount of peptide. Thus, a high mRNA-coded protein expression can be achieved for 3 days to 3 weeks.

Shortly after their ex vivo transfection, stem cells might be injected to a tissue or embedded in a medical device. The mRNA-coded protein(s) might improve stem cell survival, adhesion or differentiation, or trigger local angiogenesis.

Messenger Biopharma has demonstrated the potency of Asclepios biotechnology in human mesenchymal stem cells.

Last news

photo animalerie 3

Several companies are evaluating Messenger Biopharma’s Aegis biotechnology

posted September 03, 2018

From this Summer on, a ...Read More